1-13 of 13
George R. Blumenschein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC

Free
Marcelo V. Negrao, David Molkentine, Alvaro G. Paula, Laura Hover, Monique Nilsson, Natalie Vokes, Lars Engstrom, Andrew Calinisan, Laura Waters, David M. Briere, Jill Hallin, George R. Blumenschein, Ferdinandos Skoulidis, Scott E. Kopetz, David S. Hong, Don L. Gibbons, Peter Olson, James Christensen, John V. Heymach
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1212.
https://doi.org/10.1158/1538-7445.AM2024-1212
Published: 22 March 2024
View article titled, Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC
Journal Articles

Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141

Free
Robert L. Ferris, George R. Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L. Gillison
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT116.
https://doi.org/10.1158/1538-7445.AM2018-CT116
Published: 01 July 2018
View article titled, Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141
Journal Articles

Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

Free
Christine M. Lovly, Jeffrey R. Infante, George R. Blumenschein, Karen Reckamp, Heather Wakelee, Corey A. Carter, Saiama N. Waqar, Joel Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, Leora Horn
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT088.
https://doi.org/10.1158/1538-7445.AM2016-CT088
Published: 15 July 2016
View article titled, Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
Journal Articles

Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140)

Free
Raffit Hassan, John J. Nemunaitis, Jan P. van Meerbeeck, Ross Jennens, George R. Blumenschein, Jr, Dean A. Fennell, Hedy L. Kindler, Silvia Novello, Cem Elbi, Annette Walter, Danila Serpico, Emma Fountain, Sandra Vingerhoedt, Christine Brown, Jonathan Siegel, Barrett H. Childs
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT083.
https://doi.org/10.1158/1538-7445.AM2016-CT083
Published: 15 July 2016
View article titled, Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140)
Journal Articles

Abstract 4819: Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC)

Free
Pierre Saintigny, George R. Blumenschein, Lixia Diao, Jing Wang, Kevin Coombes, Suyu Liu, Edward Kim, Anne Tsao, Roy Herbst, Christine Alden, Jack J. Lee, Ximing Tang, David Stewart, Merrill Kies, Frank Fossella, Hai Tran, Li Mao, Marshall Hicks, Jeremy Erasmus, Sanjay Gupta, Luc Girard, Michael Peyton, Suzanne Davis, Scott Lippman, Waun Ki Hong, John Minna, Ignacio Wistuba, John Heymach
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4819.
https://doi.org/10.1158/1538-7445.AM2012-4819
Published: 15 April 2012
View article titled, Abstract 4819: Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC)
Journal Articles

Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)

Free
John V. Heymach, Pierre Saintigny, Edward S. Kim, Lauren A. Byers, J. Jack Lee, Kevin Coombes, Lixia Diao, Jing Wang, Hai Tran, You H. Fan, Anne Tsao, George R. Blumenschein, Vassiliki A. Papadimitrakopoulou, Ximing Tang, Michael Story, Yang Xie, Luc Girard, John Weinstein, Li Mao, John D. Minna, Roy Herbst, Scott M. Lippman, Waun K. Hong, Ignacio I. Wistuba
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): LB-88.
https://doi.org/10.1158/1538-7445.AM2011-LB-88
Published: 15 April 2011
View article titled, Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)
Journal Articles

Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS

Free
Pierre Saintigny, Lixia Diao, Jing Wang, Luc Girard, Steven H. Lin, Kevin R. Coombes, Suyu Liu, J. Jack Lee, John N. Weinstein, Yang Xie, You H. Fan, Xi Ming Tang, Edward S. Kim, Roy S. Herbst, Anne Tsao, George R. Blumenschein, Li Mao, Scott M. Lippman, John D. Minna, Waun Ki Hong, Ignacio I. Wistuba, John V. Heymach
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4109.
https://doi.org/10.1158/1538-7445.AM2011-4109
Published: 15 April 2011
View article titled, Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS
Journal Articles

Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer

Free
Nate T. Ihle, Roy S. Herbst, Edward S. Kim, Ignacio I. Wistuba, J.Jack Lee, George R. Blumenschein, Anne S. Tsao, Lu Chen, Shuxing Zhang, Christine M. Alden, Ximing Tang, Suyu Liu, David J. Stewart, Vassiliki Papadimitrakopoulou, John V. Heymach, Hai T. Tran, Marshall E. Hicks, Jeremy J. Erasmus, Sanjay Gupta, John D. Minna, Jill Larsen, Scott M. Lippman, Waun Ki Hong, Garth Powis
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 955.
https://doi.org/10.1158/1538-7445.AM2011-955
Published: 15 April 2011
View article titled, Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer
Journal Articles

Pathological Assessment of Response to Induction Chemotherapy in Breast Cancer

Free
Lorne D. Feldman, Gabriel N. Hortobagyi, Aman U. Buzdar, Frederick C. Ames, George R. Blumenschein
Journal: Cancer Research
Cancer Res (1986) 46 (5): 2578–2581.
Published: 01 May 1986
View article titled, Pathological Assessment of Response to Induction Chemotherapy in Breast Cancer
Open the PDF for Pathological Assessment of Response to Induction Chemotherapy in Breast Cancer in another window
Journal Articles

Normalization of in Vitro Sensitivity Testing of Human Tumor Clonogenic Cells

Free
Verena Hug, Howard Thames, George R. Blumenschein, Gary Spitzer, Benjamin Drewinko
Journal: Cancer Research
Cancer Res (1984) 44 (3): 923–928.
Published: 01 March 1984
View article titled, Normalization of in Vitro Sensitivity Testing of Human Tumor Clonogenic Cells
Open the PDF for Normalization of in Vitro Sensitivity Testing of Human Tumor Clonogenic Cells in another window
Journal Articles

Bisantrene, an Active New Drug in the Treatment of Metastatic Breast Cancer

Free
Hwee-Yong Yap, Boh-Seng Yap, George R. Blumenschein, Brian C. Barnes, Frank C. Schell, Gerald P. Bodey
Journal: Cancer Research
Cancer Res (1983) 43 (3): 1402–1404.
Published: 01 March 1983
View article titled, Bisantrene, an Active New Drug in the Treatment of Metastatic Breast Cancer
Open the PDF for Bisantrene, an Active New Drug in the Treatment of Metastatic Breast Cancer in another window
Journal Articles

Effect of Diethylaminoethyl-dextran on Colony Formation of Human Tumor Cells in Semisolid Suspension Cultures

Free
Verena Hug, Gary Spitzer, Benjamin Drewinko, George R. Blumenschein
Journal: Cancer Research
Cancer Res (1983) 43 (1): 210–213.
Published: 01 January 1983
View article titled, Effect of Diethylaminoethyl-dextran on Colony Formation of Human Tumor Cells in Semisolid Suspension Cultures
Open the PDF for Effect of Diethylaminoethyl-dextran on Colony Formation of Human Tumor Cells in Semisolid Suspension Cultures in another window
Journal Articles

Prognostic Factors in Metastatic Breast Cancer Treated with Combination Chemotherapy

Free
Kenneth D. Swenerton, Sewa S. Legha, Terry Smith, Gabriel N. Hortobagyi, Edmund A. Gehan, Hwee-Yong Yap, Jordan U. Gutterman, George R. Blumenschein
Journal: Cancer Research
Cancer Res (1979) 39 (5): 1552–1562.
Published: 01 May 1979
View article titled, Prognostic Factors in Metastatic Breast Cancer Treated with Combination Chemotherapy
Open the PDF for Prognostic Factors in Metastatic Breast Cancer Treated with Combination Chemotherapy in another window